Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
McKinsey
Citi
Cerilliant
McKesson
Baxter
Johnson and Johnson
Chinese Patent Office

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYMBALTA

« Back to Dashboard

Clinical Trials for Cymbalta

Trial ID Title Status Sponsor Phase Summary
NCT00105989 Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder Completed Boehringer Ingelheim Phase 3 The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00105989 Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder Completed Eli Lilly and Company Phase 3 The purpose of this study is to assess the efficacy and safety of duloxetine compared with placebo in the prevention of depressive recurrences among patients with recurrent major depressive disorder.
NCT00114127 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed Massachusetts General Hospital Phase 3 The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.
NCT00177671 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed National Institute of Mental Health (NIMH) Phase 4 This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
NCT00177671 Antidepressant Medication Plus Donepezil for Treating Late-life Depression Completed University of Pittsburgh Phase 4 This study will determine the effectiveness of combining escitalopram, venlafaxine, or duloxetine with donepezil, a medication used in Alzheimer's disease, in improving memory, concentration, attention, and problem solving abilities, and reducing the risk of depressive relapse in older individuals with depression.
NCT00185575 Duloxetine for the Treatment of Dysthymia Completed Eli Lilly and Company N/A The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cymbalta

Condition Name

Condition Name for Cymbalta
Intervention Trials
Major Depressive Disorder 17
Depression 13
Fibromyalgia 7
Generalized Anxiety Disorder 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cymbalta
Intervention Trials
Depression 38
Depressive Disorder 36
Depressive Disorder, Major 26
Disease 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cymbalta

Trials by Country

Trials by Country for Cymbalta
Location Trials
United States 406
Canada 26
United Kingdom 11
Germany 10
France 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cymbalta
Location Trials
New York 24
California 22
Florida 21
Ohio 20
Texas 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cymbalta

Clinical Trial Phase

Clinical Trial Phase for Cymbalta
Clinical Trial Phase Trials
Phase 4 40
Phase 3 32
Phase 2/Phase 3 3
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cymbalta
Clinical Trial Phase Trials
Completed 75
Recruiting 16
Terminated 6
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cymbalta

Sponsor Name

Sponsor Name for Cymbalta
Sponsor Trials
Eli Lilly and Company 58
Boehringer Ingelheim 7
Shionogi 7
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cymbalta
Sponsor Trials
Industry 82
Other 76
NIH 8
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKinsey
Harvard Business School
Accenture
Federal Trade Commission
Fuji
Daiichi Sankyo
Cerilliant
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.